These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1882 related articles for article (PubMed ID: 27072860)

  • 1. Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) Trial.
    Hussain I; Mohammed SF; Forfia PR; Lewis GD; Borlaug BA; Gallup DS; Redfield MM
    Circ Heart Fail; 2016 Apr; 9(4):e002729. PubMed ID: 27072860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced pulmonary vasodilator reserve and abnormal right ventricular: pulmonary artery coupling in heart failure with preserved ejection fraction.
    Andersen MJ; Hwang SJ; Kane GC; Melenovsky V; Olson TP; Fetterly K; Borlaug BA
    Circ Heart Fail; 2015 May; 8(3):542-50. PubMed ID: 25857307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study.
    Belyavskiy E; Ovchinnikov A; Potekhina A; Ageev F; Edelmann F
    BMC Cardiovasc Disord; 2020 Sep; 20(1):408. PubMed ID: 32912157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RV Contractile Function and its Coupling to Pulmonary Circulation in Heart Failure With Preserved Ejection Fraction: Stratification of Clinical Phenotypes and Outcomes.
    Guazzi M; Dixon D; Labate V; Beussink-Nelson L; Bandera F; Cuttica MJ; Shah SJ
    JACC Cardiovasc Imaging; 2017 Oct; 10(10 Pt B):1211-1221. PubMed ID: 28412423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study.
    Zakeri R; Borlaug BA; McNulty SE; Mohammed SF; Lewis GD; Semigran MJ; Deswal A; LeWinter M; Hernandez AF; Braunwald E; Redfield MM
    Circ Heart Fail; 2014 Jan; 7(1):123-30. PubMed ID: 24162898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary Vascular Distensibility Predicts Pulmonary Hypertension Severity, Exercise Capacity, and Survival in Heart Failure.
    Malhotra R; Dhakal BP; Eisman AS; Pappagianopoulos PP; Dress A; Weiner RB; Baggish AL; Semigran MJ; Lewis GD
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27301469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction.
    Borlaug BA; Lewis GD; McNulty SE; Semigran MJ; LeWinter M; Chen H; Lin G; Deswal A; Margulies KB; Redfield MM
    Circ Heart Fail; 2015 May; 8(3):533-41. PubMed ID: 25782985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction.
    AbouEzzeddine OF; McKie PM; Dunlay SM; Stevens SR; Felker GM; Borlaug BA; Chen HH; Tracy RP; Braunwald E; Redfield MM
    J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28214792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Right ventricular function and its coupling to pulmonary circulation predicts exercise tolerance in systolic heart failure.
    Legris V; Thibault B; Dupuis J; White M; Asgar AW; Fortier A; Pitre C; Bouabdallaoui N; Henri C; O'Meara E; Ducharme A;
    ESC Heart Fail; 2022 Feb; 9(1):450-464. PubMed ID: 34953062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Right ventricular function in heart failure with preserved ejection fraction: a community-based study.
    Mohammed SF; Hussain I; AbouEzzeddine OF; Takahama H; Kwon SH; Forfia P; Roger VL; Redfield MM
    Circulation; 2014 Dec; 130(25):2310-20. PubMed ID: 25391518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sildenafil treatment in established right ventricular dysfunction improves diastolic function and attenuates interstitial fibrosis independent from afterload.
    Borgdorff MA; Bartelds B; Dickinson MG; van Wiechen MP; Steendijk P; de Vroomen M; Berger RM
    Am J Physiol Heart Circ Physiol; 2014 Aug; 307(3):H361-9. PubMed ID: 24878769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Right Ventricular-Arterial Uncoupling During Exercise in Heart Failure With Preserved Ejection Fraction: Role of Pulmonary Vascular Dysfunction.
    Singh I; Rahaghi FN; Naeije R; Oliveira RKF; Systrom DM; Waxman AB
    Chest; 2019 Nov; 156(5):933-943. PubMed ID: 31103695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.
    Guazzi M; Vicenzi M; Arena R; Guazzi MD
    Circulation; 2011 Jul; 124(2):164-74. PubMed ID: 21709061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.
    Hoendermis ES; Liu LC; Hummel YM; van der Meer P; de Boer RA; Berger RM; van Veldhuisen DJ; Voors AA
    Eur Heart J; 2015 Oct; 36(38):2565-73. PubMed ID: 26188003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Left Atrial Function Dynamics During Exercise in Heart Failure: Pathophysiological Implications on the Right Heart and Exercise Ventilation Inefficiency.
    Sugimoto T; Bandera F; Generati G; Alfonzetti E; Bussadori C; Guazzi M
    JACC Cardiovasc Imaging; 2017 Oct; 10(10 Pt B):1253-1264. PubMed ID: 28017395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin and Right Ventricular-Pulmonary Vascular Interaction in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of a Randomized Clinical Trial.
    Reddy YNV; Carter RE; Sorimachi H; Omar M; Popovic D; Alogna A; Jensen MD; Borlaug BA
    JAMA Cardiol; 2024 Sep; 9(9):843-851. PubMed ID: 39046727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.
    Redfield MM; Chen HH; Borlaug BA; Semigran MJ; Lee KL; Lewis G; LeWinter MM; Rouleau JL; Bull DA; Mann DL; Deswal A; Stevenson LW; Givertz MM; Ofili EO; O'Connor CM; Felker GM; Goldsmith SR; Bart BA; McNulty SE; Ibarra JC; Lin G; Oh JK; Patel MR; Kim RJ; Tracy RP; Velazquez EJ; Anstrom KJ; Hernandez AF; Mascette AM; Braunwald E;
    JAMA; 2013 Mar; 309(12):1268-77. PubMed ID: 23478662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resting ventricular-vascular function and exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study.
    Mohammed SF; Borlaug BA; McNulty S; Lewis GD; Lin G; Zakeri R; Semigran MJ; LeWinter M; Hernandez AF; Braunwald E; Redfield MM
    Circ Heart Fail; 2014 Jul; 7(4):580-9. PubMed ID: 24833648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure).
    AbouEzzeddine OF; Haines P; Stevens S; Nativi-Nicolau J; Felker GM; Borlaug BA; Chen HH; Tracy RP; Braunwald E; Redfield MM
    JACC Heart Fail; 2015 Mar; 3(3):245-52. PubMed ID: 25742762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction.
    Bosch L; Lam CSP; Gong L; Chan SP; Sim D; Yeo D; Jaufeerally F; Leong KTG; Ong HY; Ng TP; Richards AM; Arslan F; Ling LH
    Eur J Heart Fail; 2017 Dec; 19(12):1664-1671. PubMed ID: 28597497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 95.